Last reviewed 2026-04-20 · How we verify

Diabenor (GLISOLAMIDE)

Phase 2 active Small molecule

Diabenor (generic name: GLISOLAMIDE) is a glisolamide drug. It is currently in Phase 2 development.

Diabenor works by inhibiting a specific enzyme or receptor involved in glucose regulation.

Diabenor, also known as Glisolumamide, is a small molecule drug in the glisolamide class. Its exact target and mechanism of action are unknown, but it is believed to work by inhibiting a specific enzyme or receptor involved in glucose regulation. Diabenor's commercial status and approved indications are unclear, and it is not known whether it is patented or available as a generic. Further research is needed to fully understand its effects and potential uses. As a result, key safety considerations and pharmacokinetic properties, such as half-life and bioavailability, are also unknown.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	GLISOLAMIDE
Drug class	glisolamide
Modality	Small molecule
Therapeutic area	Metabolic
Phase	Phase 2

Mechanism of action

Think of it like a key that unlocks a door. In this case, the door is a process in the body that controls blood sugar levels. Diabenor is like a key that blocks the door, preventing the process from happening and helping to lower blood sugar levels.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Diabenor CI brief — competitive landscape report
Diabenor updates RSS · CI watch RSS

Frequently asked questions about Diabenor

What is Diabenor?

Diabenor (GLISOLAMIDE) is a glisolamide drug.

How does Diabenor work?

Diabenor works by inhibiting a specific enzyme or receptor involved in glucose regulation.

What is the generic name of Diabenor?

GLISOLAMIDE is the generic (nonproprietary) name of Diabenor.

What drug class is Diabenor in?

Diabenor belongs to the glisolamide class. See all glisolamide drugs at /class/glisolamide.

What development phase is Diabenor in?

Diabenor is in Phase 2.

Drug class: All glisolamide drugs
Therapeutic area: All drugs in Metabolic

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing